Jade Biosciences (JBIO) Company presentation summary

Strategic focus and mission

• Focused on developing best-in-class therapies for critical unmet needs in autoimmune diseases, leveraging assets licensed from Paragon Therapeutics.

• Mission is to urgently deliver disease-modifying therapies that enable clinical remission for patients.

Financial position and capitalization

• $311 million in cash as of March 31, 2026, providing runway into the first half of 2028.

• 70,745,453 total outstanding shares (common and equivalents) as of March 31, 2026.

Pipeline overview and milestones

• Three main candidates: JADE101 (anti-APRIL for IgAN), JADE201 (anti-BAFF-R for systemic autoimmune diseases), and JADE301 (undisclosed).

• JADE101: Interim Phase 1 data and Phase 2 initiation expected Q2 2026; interim Phase 2 data in 2027.

• JADE201: Phase 1 initiation in Q2 2026, interim Phase 1 data in 2027; JADE301 Phase 1 initiation planned for 1H 2027.